Search for other papers by Shi-en Fu in
Google Scholar
PubMed
Search for other papers by Rou-mei Wang in
Google Scholar
PubMed
Search for other papers by Xing-huan Liang in
Google Scholar
PubMed
Search for other papers by Jing Xian in
Google Scholar
PubMed
Search for other papers by Jie Pan in
Google Scholar
PubMed
Search for other papers by Xue-lan Chen in
Google Scholar
PubMed
Search for other papers by Cheng-cheng Qiu in
Google Scholar
PubMed
Search for other papers by Zhi-ping Tang in
Google Scholar
PubMed
Search for other papers by Ying-fen Qin in
Google Scholar
PubMed
Search for other papers by Hai-yan Yang in
Google Scholar
PubMed
Department of Endocrinology, The Affiliated Hospital of Guilin Medical University, Guilin, China
Search for other papers by Li-li Huang in
Google Scholar
PubMed
Search for other papers by Ya-qi Kuang in
Google Scholar
PubMed
Search for other papers by Yan Ma in
Google Scholar
PubMed
Search for other papers by Zuo-jie Luo in
Google Scholar
PubMed
Introduction Hyperthyroidism is described as thyrotoxicosis caused by inappropriately high synthesis and secretion of thyroid hormones ( 1 ). The etiology of hyperthyroidism is classified into 12 categories, such as Graves’ disease (GD), toxic
Search for other papers by Aleksandra Krygier in
Google Scholar
PubMed
Search for other papers by Ewelina Szczepanek-Parulska in
Google Scholar
PubMed
Search for other papers by Dorota Filipowicz in
Google Scholar
PubMed
Search for other papers by Marek Ruchała in
Google Scholar
PubMed
Introduction In the biochemical landscape of thyroid dysfunction, iron (Fe) homeostasis abnormalities are frequently observed ( 1 , 2 ). The prevalence of anaemia in overt hyperthyroidism was found to be higher (14.6%) than in overt
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Jan Calissendorff in
Google Scholar
PubMed
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
Search for other papers by Henrik Falhammar in
Google Scholar
PubMed
1920s LS was given as a pre-treatment to thyroid surgery ( 3 ). It became the standard pre-operative treatment to control hyperthyroidism. However, with the development of pharmacologic agents blocking the thyroid hormone synthesis and radioactive
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by Signe Kirkegaard in
Google Scholar
PubMed
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by Nanna Maria Uldall Torp in
Google Scholar
PubMed
Department of Geriatrics, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by Stig Andersen in
Google Scholar
PubMed
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by Stine Linding Andersen in
Google Scholar
PubMed
Introduction Thyroid disorders are common endocrine disorders with a female predominance. In the reproductive age span, the disorders are mainly of autoimmune origin with hyperthyroidism being part of Graves’ disease (GD) ( 1 ), and
Search for other papers by Min Li in
Google Scholar
PubMed
Search for other papers by Ying Chen in
Google Scholar
PubMed
Search for other papers by Jingjing Jiang in
Google Scholar
PubMed
Search for other papers by Yan Lu in
Google Scholar
PubMed
Search for other papers by Zhiyi Song in
Google Scholar
PubMed
Search for other papers by Shengjie Zhang in
Google Scholar
PubMed
Search for other papers by Chao Sun in
Google Scholar
PubMed
Search for other papers by Hao Ying in
Google Scholar
PubMed
Search for other papers by Xiaofang Fan in
Google Scholar
PubMed
Search for other papers by Yuping Song in
Google Scholar
PubMed
Search for other papers by Jialin Yang in
Google Scholar
PubMed
Search for other papers by Lin Zhao in
Google Scholar
PubMed
mainly expressed in the liver ( 1 , 2 ). Hyperthyroidism, a state of excessive TH, is characterized by increased resting energy expenditure, weight loss, reduced cholesterol levels, enhanced lipolysis and hepatic gluconeogenesis ( 3 ). Besides, recent
Search for other papers by Ayse Nurcan Cebeci in
Google Scholar
PubMed
Search for other papers by Vera Schempp in
Google Scholar
PubMed
Search for other papers by Katharina Förtsch in
Google Scholar
PubMed
Search for other papers by Bettina Gohlke in
Google Scholar
PubMed
Search for other papers by Michaela Marx in
Google Scholar
PubMed
Search for other papers by Helmuth-Guenther Dörr in
Google Scholar
PubMed
Search for other papers by Joachim Woelfle in
Google Scholar
PubMed
Introduction Graves’ disease (GD) is the primary aetiology of hyperthyroidism in children and adolescents, with a prevalence of about 1 in 10,000 ( 1 ). Down syndrome (DS) is one of the most common chromosomal disorders, occurring in nearly 1
Search for other papers by Madalena von Hafe in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João, Porto, Portugal
Search for other papers by João Sergio Neves in
Google Scholar
PubMed
Search for other papers by Catarina Vale in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar São João, Porto, Portugal
Search for other papers by Marta Borges-Canha in
Google Scholar
PubMed
Search for other papers by Adelino Leite-Moreira in
Google Scholar
PubMed
preventing heart failure ( 34 ). Cardiovascular effects of hyperthyroidism Hyperthyroidism is characterized biochemically by low TSH levels and elevated free T4, free T3 or both. The prevalence of overt hyperthyroidism in the general population is 0
Search for other papers by Peter D Mark in
Google Scholar
PubMed
Search for other papers by Mikkel Andreassen in
Google Scholar
PubMed
Department of Medicine O, Department of Clinical Physiology and Nuclear Medicine, Department of Clinical Physiology, Faculty of Health Sciences, Center for Functional and Diagnostic Imaging and Research, Centre of Endocrinology and Metabolism, Herlev University Hospital, Herlev Ringvej 75, Herlev DK‐2730, Denmark
Search for other papers by Claus L Petersen in
Google Scholar
PubMed
Department of Medicine O, Department of Clinical Physiology and Nuclear Medicine, Department of Clinical Physiology, Faculty of Health Sciences, Center for Functional and Diagnostic Imaging and Research, Centre of Endocrinology and Metabolism, Herlev University Hospital, Herlev Ringvej 75, Herlev DK‐2730, Denmark
Search for other papers by Andreas Kjaer in
Google Scholar
PubMed
Department of Medicine O, Department of Clinical Physiology and Nuclear Medicine, Department of Clinical Physiology, Faculty of Health Sciences, Center for Functional and Diagnostic Imaging and Research, Centre of Endocrinology and Metabolism, Herlev University Hospital, Herlev Ringvej 75, Herlev DK‐2730, Denmark
Search for other papers by Jens Faber in
Google Scholar
PubMed
Background Subclinical hyperthyroidism (SH) is defined by the biochemical pattern of reduced or undetectable serum thyroid-stimulating hormone (TSH) levels and thyroid hormone levels within the reference range. SH is seen with increasing frequency
Search for other papers by M L M Barreto-Chaves in
Google Scholar
PubMed
Search for other papers by N Senger in
Google Scholar
PubMed
Search for other papers by M R Fevereiro in
Google Scholar
PubMed
Search for other papers by A C Parletta in
Google Scholar
PubMed
Search for other papers by A P C Takano in
Google Scholar
PubMed
some examples of disorders that can lead to hyperthyroidism ( 16 ). In this context, overt hyperthyroidism is characterized by high levels of T3 and T4, and decreased TSH levels. However, the most usual type of hyperthyroidism observed in medical
Search for other papers by Danzhou Fang in
Google Scholar
PubMed
Search for other papers by Shiying Li in
Google Scholar
PubMed
Search for other papers by Yirui Wang in
Google Scholar
PubMed
Search for other papers by Yue Chen in
Google Scholar
PubMed
Search for other papers by Gengbiao Yuan in
Google Scholar
PubMed
Search for other papers by Maohua Rao in
Google Scholar
PubMed
Objective: Hyperthyroidism, a prevalent endocrine disorder, can lead to complications such as liver failure due to the liver's essential role in thyroid hormone metabolism. The study aimed to elucidate the respective contributions of 131I or/and ALSS in managing hyperthyroidism alongside liver failure.
Methods: A retrospective analysis was carried out on 74 patients diagnosed with severe liver failure in the context of Graves' disease. Patients were categorized into three groups: Group A (n=34) received 131I treatment, group B (n=17) underwent 131I and ALSS treatment, and group C (n=24) received ALSS treatment alone.
Results: Throughout the treatment period, the liver function indexes in all groups exhibited a decline trend. The thyroid function of group A and group B treated with 131I was significantly improved compared with that before treatment. There was no significant change in thyroid function in group C. After the correction of hyperthyroidism, significant improvements were observed in the liver function of individuals in group A and B, particularly with more noticeable amelioration compared to group C. After two months of treatment, the efficacy rates for the three groups were 79.41%, 82.35%, and 60.87% respectively. Mortality rates of the three groups were 5.88%,17.65% and 36% (p<0.01). Group B, receiving both 131I and ALSS treatments, exhibited a lower mortality rate than group C.
Conclusion: In cases of severe liver failure accompanied by hyperthyroidism, prompt administration of 131I is recommended to alleviate the adverse effects of hyperthyroidism on liver function and facilitate a conducive environment for the recovery of liver functionality.